Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.
The ubiquitous Epstein-Barr virus (EBV) infects not only B cells but also T cells and natural killer (NK) cells and is associated with various lymphoid malignancies. Recent studies have reported that histone deacetylase (HDAC) inhibitors exert anticancer effects against various tumor cells. In the present study, we have evaluated both the in vitro and in vivo effects of suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor, on EBV-positive and EBV-negative T and NK lymphoma cells. Several EBV-positive and EBV-negative T and NK cell lines were treated with various concentrations of SAHA. SAHA suppressed the proliferation of T and NK cell lines, although no significant difference was observed between EBV-positive and EBV-negative cell lines. SAHA induced apoptosis and/or cell cycle arrest in several T and NK cell lines. In addition, SAHA increased the expression of EBV-lytic genes and decreased the expression of EBV-latent genes. Next, EBV-positive NK cell lymphoma cells were subcutaneously inoculated into severely immunodeficient NOD/Shi-scid/IL-2Rγnull mice, and then SAHA was administered intraperitoneally. SAHA inhibited tumor progression and metastasis in the murine xenograft model. SAHA displayed a marked suppressive effect against EBV-associated T and NK cell lymphomas through either induction of apoptosis or cell cycle arrest, and may represent an alternative treatment option.
Department of Virology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Mohammed N A
MN
Siddiquey
Hikaru
H
Nakagawa
Seiko
S
Iwata
Tetsuhiro
T
Kanazawa
Michio
M
Suzuki
Ken-Ichi
K
Imadome
Shigeyoshi
S
Fujiwara
Fumi
F
Goshima
Takayuki
T
Murata
Hiroshi
H
Kimura
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D045744:Cell Line, Tumor; D018450:Disease Progression; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy*; D005260:Female; D004854:Herpesvirus 4, Human; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use*; D053631:Interleukin Receptor Common gamma Subunit / Q000235:genetics; D019169:Jurkat Cells; D007694:Killer Cells, Natural / Q000821:virology; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000821:virology; D051379:Mice; D016688:Mice, Inbred NOD; D018345:Mice, Knockout; D016513:Mice, SCID; D009362:Neoplasm Metastasis; D009368:Neoplasm Transplantation; D013601:T-Lymphocytes / Q000821:virology; D014183:Transplantation, Heterologous; D000077337:Vorinostat; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; C507942:Il2rg protein, mouse; D053631:Interleukin Receptor Common gamma Subunit; D000077337:Vorinostat
Extranodal NK-T-cell lymphoma; SCID mice; histone deacetylase inhibitor; human herpesvirus 4; hydroxamic acid